JPM 2026 Recap
AI isn't just changing pharma—it's fundamentally rewriting the rules of what's possible.
Here's what we heard, what we shared, and how to continue the conversation.
Key Themes from JPM 2026
The conversations that defined the conference—and where BioCompute fits in.
From Observation to Prediction
The industry is shifting from 'observe → test' to 'model → predict → verify'—compressing drug discovery timelines from 10-15 years to just a handful.
Trust is the Bottleneck
Better models alone won't win. Adoption depends on trust, workflow fit, and auditability. If a scientist can't explain it, if it doesn't fit the day, if it can't be monitored—it dies.
Direct Functional Measurement
Moving beyond inferred biomarkers to direct functional measurement—like real-time DDR kinetics—unlocks actionable insights for stratification and resistance monitoring.
Multimodal AI Decisions
Diagnostics are evolving from single-modality answers to multimodal decisions—combining imaging, omics, clinical context, and outcomes in unified workflows.
The Reality Check
"Trust and auditability aren't features—they're the deployment gatekeepers. This won't be won by 'better models.' It will be won by adoption, trust, workflow fit, and auditability."
Industry consensus at JPM 2026
What BioCompute Brought to JPM
Our focus: bridging innovation and compliance for life sciences AI.
Sovereign AI Platform
Telemetry Airlock + Evidence Engine lineage ensures regulated multimodal execution—de-risking AI deployment from discovery to submissions.
intoDNA STRIDE® Integration
Functional DDR kinetics add molecular ground truth to multimodal stacks—moving from morphological inference to direct, actionable biomarker insights.
Immutable Evidence Chains
Every AI model decision tracked with full lineage—the traceability and monitoring infrastructure that separates pilot projects from production systems.
The Path Forward
What the industry leaders told us they need
Smart partnerships—each side brings something irreplaceable: clinical ground truth + data rights, compute, validation, and scaled deployment.
Real-world evidence that becomes a learning loop improving care every week—not static reports filed and forgotten.
Compliance architecture from day one—organizations that solve for innovation AND compliance are the ones that scale successfully.
Trials that are selective and adaptive—better patient matching, earlier stop/go decisions, less wasted time.
Build the factory once—data + models + evidence + deployment—then launch many care-grade products across pathways.
Safe failure in the wild—evaluation, traceability, and monitoring are the new competitive moats.
Continue the Conversation
Whether we connected at JPM or you're reaching out for the first time—let's talk.
Prefer to email directly?
[email protected]